Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Meningioma 1Medulloblastoma 1

Interventions

gallium Ga 68 dotatate 4fluorodopa F 18 2Magnetic Resonance Spectroscopy 2pertuzumab 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1arginyllysine 1Whole Body Imaging 1Tretinoin 1Nivolumab 1Isotretinoin 1Furosemide 1Erlotinib Hydrochloride 1Amino Acids 190Y-octreotide, DOTA-Tyr(3)- 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 13-fluorobenzylguanidine 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Whole Body Imaging × NET × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡